Oncology

Julie Vose, MD, professor of internal medicine and division chief, Division of Oncology and Hematology, University of Nebraska Medical Center, discussed the use of CAR T-cell therapy in non-Hodgkin lymphoma.

The ongoing phase 1 UNIVERSAL trial has demonstrated an overall response rate of 60% among 10 patients.

The chair of the Lymphoma Group at Mayo Clinic discussed incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

The professor from the University of Texas Anderson Cancer Center discussed challenges surrounding CAR T-cell therapy for the treatment of follicular lymphoma and other lymphomas.

The professor and chief, of oncology and hematology at University of Nebraska Medical Center discussed research with CAR T therapy in lymphoma.

The lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.

David G. Maloney, MD, PhD, covered the importance of standardized criteria in managing CRS and ICANS with CAR T therapy.

The chief executive and chief medical officer of Celyad Oncology discussed the advantages of allogeneic CAR T therapies over autologous ones.

The professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, New York-Presbyterian Hospital, discussed utility of cellular therapies in multiple myeloma.

Experts discuss the use and selection of CAR T therapies in relapsed/refractory diffuse large B-cell lymphoma.

Parexel cell and gene therapy director Izaskun Elorza, MD, shares key factors for industry to consider as this emerging field becomes more prominent.

The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed factors to consider in selecting CAR T-cell therapies.

Noa Biran, MD, discusses exciting new agents in the field that may fulfill unmet patient needs.

The Regional Care Network Medical Site Director at Memorial Sloan Kettering Cancer Center Basking Ridge discussed patient factors to consider when selecting treatment in R/R MCL.

The non-randomized, open-label trial of AIC100 is currently recruiting patients at the Weill Cornell Medical College in in New York.

The associate member in the Department of Malignant Hematology at Moffitt Cancer Center discussed results of the ZUMA-3 trial.

CAR T-cell therapy showed promising results in acute myeloid leukemia at ASCO 2021.

The inaugural leader of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, University of Miami discussed exciting novel therapeutic approaches in multiple myeloma.

Jan Philipp Bewersdorf, MD, hospital resident at Yale University School of Medicine discussed the safety and efficacy of allogeneic hematopoietic stem cell transplant in myelofibrosis.

The president and chief operating officer of Agenus discussed the cell therapies the company is developing for the treatment of multiple myeloma.

The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed emerging CAR T-cell therapies in hematologic malignancies.

Celularity and Imugene are collaborating on the novel approach to treatment of solid tumors.

The executive vice president of research and development at Jasper Therapeutics discussed positive data from trials of JSP191 in MDS and AML.

The chief executive officer of CG Oncology discussed the role of CG0070 in patients who are unresponsive and responsive to Bacillus Calmette-Guerin immunotherapy.

The clinical associate professor from the Rogel Cancer Center at Michigan Medicine discussed the future of CAR T-cell therapy in mantle cell lymphoma patients.

Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio, discussed upcoming research on MB-101 cell therapy.

The lymphoma service chief at Memorial Sloan Kettering Cancer Center discussed the need for new therapies to treat diffuse large B-cell lymphoma.

Loretta Nastoupil, MD, and John Burke, MD, discussed treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

The executive vice president of research and development at Jasper Therapeutics discussed how JSP191 is designed to be better-tolerated than current conditioning regimens.

The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.